Table 3.
Control arm | Arm 1 | Arm 2 | Chi-square | P | |
Amylasemia at 6 h | 4.288 | 0.368 | |||
< 3 × ULN | 81.6% | 100.0% | 85.7% | ||
> 3 × ULN | 18.4% | 0.0% | 14.3% | ||
Lipasemia at 6 h | 10.046 | 0.040 | |||
< 3 × ULN | 69.4% | 68.7% | 71.4% | ||
> 3 × ULN | 30.6% | 31.3% | 28.6% | ||
CRP at 6 h | 12.165 | 0.058 | |||
Normal | 49.0% | 56.2% | 57.1% | ||
Mild increase | 20.4% | 12.5% | 35.7% | ||
Moderate increase | 26.5% | 31.2% | 0.0% | ||
Severe increase | 4.1% | 0.0% | 7.1% | ||
Clinico-biologic status at 6 h | 0.397 | 0.820 | |||
PEP absent | 91.8% | 87.5% | 92.9% | ||
PEP | 8.2% | 12.5% | 7.1% |
Arm 1: Study group A treatment regimen;
Arm 2: Study group B treatment regimen; CRP: C-reactive peptide; ULN: Upper limit of normal; PEP: Post-endoscopic retrograde cholangiopancreatography pancreatitis.